FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Multiple myeloma was once viewed as an incurable diagnosis, but Ameet Patel, MD, of Florida Cancer Specialists & Research ...

Colon cancer survivor Vivian Chee has had three lung surgeries since 2021 but continues to keep fit. Read more at straitstimes.com. Read more at straitstimes.com.

The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...

In a new study published in Cancer, researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine’s Department of Pathology examine this disparity more closely, ...

Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...